Compare FEIM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEIM | BOLD |
|---|---|---|
| Founded | 1961 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 26.9M |
| IPO Year | N/A | 2024 |
| Metric | FEIM | BOLD |
|---|---|---|
| Price | $57.11 | $1.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $42.50 | $4.00 |
| AVG Volume (30 Days) | ★ 358.2K | 122.7K |
| Earning Date | 12-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.76 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $69,852,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $25.96 | ★ N/A |
| Revenue Growth | ★ 16.06 | N/A |
| 52 Week Low | $13.69 | $1.00 |
| 52 Week High | $59.38 | $2.77 |
| Indicator | FEIM | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 72.40 | 65.02 |
| Support Level | $47.54 | $1.14 |
| Resistance Level | $57.95 | $1.24 |
| Average True Range (ATR) | 4.28 | 0.08 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 88.01 | 71.74 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.